Q-omics provides the consensus-scored RPL17P20 profile across patient tissues and cancer cell-line models. RPL17P20 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RPL17P20 is differentially expressed in 5, with the highest sampling consensus in STAD. Additionally, RPL17P20 RNA expression shows 4,416 significant pathway-activity associations, with the highest sampling consensus in OV. Together, these results highlight LUAD, STAD, and OV as cancer lineages where RPL17P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL17P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL17P20 survival associations across molecular data types. RPL17P20 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL17P20 RNA expression–survival associations across cancer types. High RPL17P20 expression shows unfavorable associations in DLBC, UCEC and KICH, but favorable associations in LUAD, READ and CESC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify LUAD as the clearest survival context for RPL17P20 RNA expression.
This table summarizes RPL17P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL17P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL17P20 shows lower tumor expression in THCA and higher tumor expression in STAD, LUAD, COAD and KIRC. The STAD box plot shows higher RPL17P20 RNA expression in tumor versus normal tissue (log2 FC = +0.190, t-test p = .040).
This table shows molecular features associated with RPL17P20 in patient tissues and cancer cell lines. In patient samples, RPL17P20 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
